Biohaven Ltd. (NYSE: BHVN) reported clinical data for two experimental drugs targeting autoimmune diseases, according to a company press release.

BHV-1300, being tested for Graves' disease, achieved mean reductions of more than 80% in pathogenic TSHR-IgG1 antibodies over 12 weeks in patients receiving 1000 mg subcutaneous weekly doses. Patients with elevated thyroid hormones experienced normalization of free T4 at a median of 3 weeks and free T3 at a median of 5 weeks after initial treatment.

BHV-1400, designed for IgA nephropathy treatment, demonstrated mean reductions of more than 60% in galactose-deficient IgA1 within 48 hours and 70% reductions within one month of dosing. The company reported preliminary observations of increased estimated glomerular filtration rate, decreased urine protein-creatinine ratio, and reduced blood in urine within one month of treatment.

Both drugs showed what the company described as favorable safety profiles with no drug discontinuations and no serious or severe adverse events reported during the studies. Most adverse events were characterized as mild and self-resolving.

Biohaven plans to initiate Phase 3 trials for both treatments by mid-2026. The studies will evaluate BHV-1300 for normalization of thyroid hormones in Graves' disease patients and BHV-1400 for urine protein-creatinine ratio and kidney function in IgA nephropathy patients.

The data was presented at the company's research and development day as part of the Yale Innovation Summit in New Haven, Connecticut.